These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
191 related items for PubMed ID: 14722234
21. Peptide/benzodiazepine hybrids as ligands of CCK(A) and CCK(B) receptors. Escherich A, Lutz J, Escrieut C, Fourmy D, van Neuren AS, Müller G, Schafferhans A, Klebe G, Moroder L. Biopolymers; ; 56(2):55-76. PubMed ID: 11592053 [Abstract] [Full Text] [Related]
26. Refinement of the conformation of a critical region of charge-charge interaction between cholecystokinin and its receptor. Ding XQ, Pinon DI, Furse KE, Lybrand TP, Miller LJ. Mol Pharmacol; 2002 May; 61(5):1041-52. PubMed ID: 11961122 [Abstract] [Full Text] [Related]
30. Identification of a region of the N-terminal of the human CCKA receptor essential for the high affinity interaction with agonist CCK. Kennedy K, Escrieut C, Dufresne M, Clerc P, Vaysse N, Fourmy D. Biochem Biophys Res Commun; 1995 Aug 24; 213(3):845-52. PubMed ID: 7654246 [Abstract] [Full Text] [Related]
33. Topological analysis of the complex formed between neurokinin A and the NK2 tachykinin receptor. Zoffmann S, Bertrand S, Do QT, Bertrand D, Rognan D, Hibert M, Galzi JL. J Neurochem; 2007 Apr 24; 101(2):506-16. PubMed ID: 17402972 [Abstract] [Full Text] [Related]
35. Demonstration of a specific site of covalent labeling of the human motilin receptor using a biologically active photolabile motilin analog. Matsuura B, Dong M, Coulie B, Pinon DI, Miller LJ. J Pharmacol Exp Ther; 2005 Jun 24; 313(3):1101-8. PubMed ID: 15677347 [Abstract] [Full Text] [Related]
36. Complex of an active mu-opioid receptor with a cyclic peptide agonist modeled from experimental constraints. Fowler CB, Pogozheva ID, Lomize AL, LeVine H, Mosberg HI. Biochemistry; 2004 Dec 21; 43(50):15796-810. PubMed ID: 15595835 [Abstract] [Full Text] [Related]
37. Discovery of 1,5-benzodiazepines with peripheral cholecystokinin (CCK-A) receptor agonist activity. 1. Optimization of the agonist "trigger". Aquino CJ, Armour DR, Berman JM, Birkemo LS, Carr RA, Croom DK, Dezube M, Dougherty RW, Ervin GN, Grizzle MK, Head JE, Hirst GC, James MK, Johnson MF, Miller LJ, Queen KL, Rimele TJ, Smith DN, Sugg EE. J Med Chem; 1996 Jan 19; 39(2):562-9. PubMed ID: 8558528 [Abstract] [Full Text] [Related]
38. Identification of two amino acids of the human cholecystokinin-A receptor that interact with the N-terminal moiety of cholecystokinin. Kennedy K, Gigoux V, Escrieut C, Maigret B, Martinez J, Moroder L, Fréhel D, Gully D, Vaysse N, Fourmy D. J Biol Chem; 1997 Jan 31; 272(5):2920-6. PubMed ID: 9006937 [Abstract] [Full Text] [Related]
39. Direct identification of a second distinct site of contact between cholecystokinin and its receptor. Hadac EM, Pinon DI, Ji Z, Holicky EL, Henne RM, Lybrand TP, Miller LJ. J Biol Chem; 1998 May 22; 273(21):12988-93. PubMed ID: 9582333 [Abstract] [Full Text] [Related]
40. Direct demonstration of unique mode of natural peptide binding to the type 2 cholecystokinin receptor using photoaffinity labeling. Dong M, Miller LJ. Peptides; 2013 Aug 22; 46():143-9. PubMed ID: 23770253 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]